Results 191 to 200 of about 587,928 (338)

Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophages

open access: yesCancer Communications, EarlyView.
Abstract Background Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM.
Rongrong Zhao   +11 more
wiley   +1 more source

Immunosuppressive JAG2+ tumor‐associated neutrophils hamper PD‐1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells

open access: yesCancer Communications, EarlyView.
Abstract Background Tumor‐associated neutrophils (TANs) play a critical role in modulating immune responses and exhibit significant heterogeneity. Our previous study demonstrated that jagged canonical Notch ligand 2 (JAG2)+ TANs were associated with an immunosuppressive microenvironment in high‐grade serous ovarian cancer (HGSOC), but the underlying ...
Chenyang Wang   +11 more
wiley   +1 more source

Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation

open access: yesCancer Communications, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is a deadly malignancy known for its ability to evade immune surveillance. NOP2/Sun RNA methyltransferase family member 2 (NSUN2), an RNA methyltransferase involved in carcinogenesis, has been associated with immune evasion and energy metabolism reprogramming.
Jinhua Jiang   +6 more
wiley   +1 more source

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer. [PDF]

open access: yesJ Hematol Oncol
Deng D   +12 more
europepmc   +1 more source

Combating cancer immunotherapy resistance: a nano‐medicine perspective

open access: yesCancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong   +10 more
wiley   +1 more source

NSUN2/ALYREF axis-driven m<sup>5</sup>C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer. [PDF]

open access: yesCancer Immunol Immunother
Yang Y   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy